Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Biden redefines Trump’s populism in his own image

President Joe Biden’s address to the nation on April 28th wasn’t just a victory lap for the accomplishments of his first 100 days: It was a declaration that the Biden administration’s highest ambition would be reviving America and its democracy from the sorry state his predecessor had left it in.

There have been real accomplishments, like the transformative American Rescue Plan. But in key policy areas, even ones where Trump’s approach deeply damaged America’s democratic image, the Biden administration has seemingly been content with continuing its predecessor’s policies. On immigration and the global Covid-19 response in particular, Biden has seemed unable or unwilling to move past Donald Trump’s worldview, giving “America First” a home in a Democratic White House.

In mid-April, the Biden administration announced it would maintain the Trump administration’s 15,000-person cap on refugee admittance — a break with its campaign promise, not to mention a continuation of one of Trump’s most noxious policies.

Source: VOX

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!